Skip to content
PreclinicalResearch compound

THG (Tetrahydrogestrinone)

Banned anabolic steroid designed to evade doping tests; studied only in the lab, never in humans.

THG (Tetrahydrogestrinone) vial

DETAILED OVERVIEW

What is THG (Tetrahydrogestrinone)?

THG (Tetrahydrogestrinone) is a man-made anabolic steroid, a compound that imitates the effect of testosterone. It was designed specifically so that doping tests could not detect it, and it was sold to athletes under the name “The Clear”. It can be detected today, it is banned in competitive sport all year round, and it is a controlled substance in the United States. It has never been approved as a medicine.

In lab tests it showed strong testosterone-like and progesterone-like (similar to a female sex hormone) effects. So far only lab studies have been done, and it has never been tested in a controlled clinical trial in humans, so its side effects and long-term safety are unknown. The usual effects of such steroids, such as acne, hair loss, suppression of the body's own testosterone production and worse cholesterol values, are likely; because of its progesterone-like action the level of the hormone prolactin may also rise. It must not be used by women or in pregnancy, because it can cause masculinization and harm to the fetus.

Mechanism

AR agonist + progesterone-receptor agonist, designer non-aromatizing

Anabolic:Androgenic

Extrapolated ~150:75 (no clinical trial)

Half-life

~16-24 hours (extrapolated from gestrinone)

Onset

About 12-24 hours, with an oil solution dropped under the tongue

Legal status

Schedule III (USA 2004), never an Rx, WADA-banned

Data console

Lab data

Androgenic:AnabolicExtrapolated ~150:75 (no clinical trial)
AR bindingHigh AR affinity + moderate progesterone receptor (PR)…
Active half-life~16-24 h
Detection windowModern LC-MS/MS WADA labs: direct parent compound + tetrahydro-Δ9,11 metabolite detection 2-3 weeks urinary. Pre-2003 NOT detectable → the classical BALCO era (late 1990s-2003) was therefore practically a clean doping zone.
AromatizationNo – tetrahydro-triene structure NOT a CYP19 substrate; designer purpose explicit non-aromatizing (Catlin 2002 PMID 12352283, Death 2004 PMID 15579773)
HepatotoxicityData missing – no peer-reviewed clinical trial. Structurally NOT 17α-alkylated, so expected low-moderate hepatotoxicity (extrapolated from gestrinone). But long-term safety profile completely unknown.

Safety

Side effects, stop signs, contraindications

Side effects · 7

  • Classic androgenic effects (acne, oily skin, scalp hair loss in men) from strong AR agonism – expected for the AAS class, though no human THG data exist.
  • HPG-axis (HPTA) suppression: shutdown of endogenous testosterone, LH and FSH, with low libido and testicular atrophy, potentially requiring PCT.
  • Progesterone-receptor (PR) agonism: progestogenic effects (possible prolactin elevation, gyno risk despite the compound NOT aromatizing) – warranting prolactin monitoring.
  • Unfavorable lipid shift (HDL reduction) and potential cardiovascular strain typical of anabolic steroids – no THG-specific clinical data.
  • Disruption of hepatic glucocorticoid signalling: in vitro the THG binds non-selectively and affects glucocorticoid signalling in the liver, with potential metabolic impact (Friedel/Diel 2006, PMID 16356667).
  • Psychological effects from individual case reports (Marion Jones grand jury testimony): anxiety, sleep disturbance – uncontrolled, anecdotal data only.
  • UNKNOWN long-term safety profile: THG was NEVER studied in humans in controlled trials, so the true side-effect spectrum, frequency and severity are unknown.

Contraindications · 7

  • Women, especially during or planning pregnancy: strong androgenic + progestogenic activity can cause virilization and fetal harm (teratogenic risk).
  • Any WADA / drug-tested athlete: THG has been detectable since 2003 and is banned year-round (WADA S1.1.a); its designer 'undetectable' purpose is gone.
  • Fertility preservation / planned fatherhood: HPG-axis suppression and progestogenic activity impair spermatogenesis and fertility.
  • Pre-existing cardiovascular disease or adverse lipids: the HDL-lowering and cardiovascular-strain profile of AAS is a relative contraindication.
  • Hormone-sensitive (androgen- or progesterone-receptor-positive) cancers, e.g. suspected prostate cancer: AR/PR agonism may stimulate tumor growth.
  • Hyperprolactinemia or prolactin-sensitive conditions: PR activity can raise prolactin and worsen the existing state.
  • General caution: NO human clinical safety data exist, so any human use of THG is unjustified and not recommended – historical/educational interest only.

Related Performance Compounds

Same therapeutic category

Studies

Related research and clinical findings

Telegram

Have a question about THG (Tetrahydrogestrinone)?

Reach out to an advisor on Telegram. Performance compounds are presented with a harm-reduction approach, based on peer-reviewed evidence.

Personalized consultation

Want a detailed conversation tailored to your data?

Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.

Fill out the form

~5–7 min · prep questionnaire · confidential · GDPR-compliant

MolekulaX Editorial Team·Source-verified · PubMed · FDA · EMA
Updated: October 14, 2026

The information here is for educational and scientific purposes only. Performance-enhancing compounds (AAS, prohormones, stimulants, doping agents) are illegal without prescription in Hungary and most of the EU, and carry serious health and legal risks. WADA bans them in competitive sport. This is NOT a usage guide, and we do not encourage any illegal use. If you do use them, medical supervision and regular bloodwork are ESSENTIAL. Severe endocrine, cardiovascular, hepatic and psychiatric side effects are possible.